Attenuation of Nitrogen Mustard-Induced Pulmonary Injury and Fibrosis by Anti-Tumor Necrosis Factor-α Antibody

被引:50
|
作者
Malaviya, Rama [1 ]
Sunil, Vasanthi R. [1 ]
Venosa, Alessandro [1 ]
Verissimo, Vivianne L. [1 ]
Cervelli, Jessica A. [1 ]
Vayas, Kinal N. [1 ]
Hall, LeRoy [3 ]
Laskin, Jeffrey D. [2 ]
Laskin, Debra L. [1 ]
机构
[1] Rutgers State Univ, Dept Pharmacol & Toxicol, Ernest Mario Sch Pharm, Piscataway, NJ 08854 USA
[2] Rutgers State Univ, Dept Environm & Occupat Med, Robert Wood Johnson Med Sch, Piscataway, NJ 08854 USA
[3] Janssen Res & Dev, Dept Drug Safety Sci, Raritan, NJ 08869 USA
基金
美国国家卫生研究院;
关键词
alveolar macrophages; lung injury; vesicant; fibrosis; ACUTE LUNG INJURY; SULFUR MUSTARD; MACROPHAGE ACTIVATION; TISSUE-INJURY; MURINE MODEL; TNF-ALPHA; INFLAMMATION; EXPRESSION; MECHANISMS; RECEPTOR;
D O I
10.1093/toxsci/kfv161
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
Nitrogen mustard (NM) is a bifunctional alkylating agent that causes acute injury to the lung that progresses to fibrosis. This is accompanied by a prominent infiltration of macrophages into the lung and upregulation of proinflammatory/profibrotic cytokines including tumor necrosis factor (TNF)alpha. In these studies, we analyzed the ability of anti-TNF alpha antibody to mitigate NM-induced lung injury, inflammation, and fibrosis. Treatment of rats with anti-TNF alpha antibody (15 mg/kg, iv, every 9 days) beginning 30 min after intratracheal administration of NM (0.125 mg/kg) reduced progressive histopathologic alterations in the lung including perivascular and peribronchial edema, macrophage/monocyte infiltration, interstitial thickening, bronchiolization of alveolar walls, fibrin deposition, emphysema, and fibrosis. NM-induced damage to the alveolar-epithelial barrier, measured by bronchoalveolar lavage (BAL) protein and cell content, was also reduced by anti-TNF alpha antibody, along with expression of the oxidative stress marker, heme oxygenase-1. Whereas the accumulation of proinflammatory/cytotoxic M1 macrophages in the lung in response to NM was suppressed by anti-TNF alpha antibody, antiinflammatory/profibrotic M2 macrophages were increased or unchanged. Treatment of rats with anti-TNF alpha antibody also reduced NM-induced increases in expression of the profibrotic mediator, transforming growth factor-beta. This was associated with a reduction in NM-induced collagen deposition in the lung. These data suggest that inhibiting TNF alpha may represent an efficacious approach to mitigating lung injury induced by mustards.
引用
收藏
页码:71 / 88
页数:18
相关论文
共 50 条
  • [21] Anti-tumor necrosis factor-α therapy-induced vasculitis:: Case series
    Jarrett, SJ
    Cunnane, G
    Conaghan, PG
    Bingham, SJ
    Buch, MH
    Quinn, MA
    Emery, P
    JOURNAL OF RHEUMATOLOGY, 2003, 30 (10) : 2287 - 2291
  • [22] Tumor necrosis factor-α in cardiovascular biology and the potential role for anti-tumor necrosis factor-α therapy in heart disease
    Sack, MN
    PHARMACOLOGY & THERAPEUTICS, 2002, 94 (1-2) : 123 - 135
  • [23] Characterization of Distinct Macrophage Subpopulations during Nitrogen Mustard-Induced Lung Injury and Fibrosis
    Venosa, Alessandro
    Malaviya, Rama
    Choi, Hyejeong
    Gow, Andrew J.
    Laskin, Jeffrey D.
    Laskin, Debra L.
    AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 2016, 54 (03) : 436 - 446
  • [24] Compromised anti-tumor responses in tumor necrosis factor-α knockout mice
    Baxevanis, CN
    Voutsas, IF
    Tsitsilonis, OE
    Tsiatas, ML
    Gritzapis, AD
    Papamichail, M
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2000, 30 (07) : 1957 - 1966
  • [25] Pulmonary Sarcoidosis Induced by Anti-Tumor Necrosis Factor Therapy A Paradoxical Effect
    Vigano Pugliesi, Alisson Aliel
    Mariano, Rachel Zerbini
    De Angelis, Camila Matsunaga
    Bertolo, Manoel Barros
    Yazbek, Michel Alexandre
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2020, 26 (01) : E23 - E24
  • [26] Adalimumab, a novel anti-tumor necrosis factor-α antibody in a child with refractory Crohn's disease
    Mian, S
    Baron, H
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2005, 41 (03): : 357 - 359
  • [27] Histoplasmosis after treatment with anti-tumor necrosis factor-α therapy
    Wood, KL
    Hage, CA
    Knox, KS
    Kleiman, MB
    Sannuti, A
    Day, RB
    Wheat, LJ
    Twigg, HL
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2003, 167 (09) : 1279 - 1282
  • [28] Nontuberculous Mycobacteria Infections and Anti-Tumor Necrosis Factor-α Therapy
    Winthrop, Kevin L.
    Chang, Eric
    Yamashita, Shellie
    Lademarco, Michael F.
    LoBue, Philip A.
    EMERGING INFECTIOUS DISEASES, 2009, 15 (10) : 1556 - 1561
  • [29] Vasculoprotective effects of anti-tumor necrosis factor-α treatment in aging
    Csiszar, Anna
    Labinskyy, Nazar
    Smith, Kira
    Rivera, Aracelie
    Orosz, Zsuzsanna
    Ungvari, Zoltan
    AMERICAN JOURNAL OF PATHOLOGY, 2007, 170 (01): : 388 - 398
  • [30] Tuberculosis and Biologic Therapies Anti-Tumor Necrosis Factor-α and Beyond
    Godfrey, Mark S.
    Friedman, Lloyd N.
    CLINICS IN CHEST MEDICINE, 2019, 40 (04) : 721 - +